Thus, this study aimed to: (a) evaluate the association between SGLT2 inhibitors and incident heart failure, as well as other non‐heart‐failure‐related adverse cardiovascular events such as mortality, arrhythmias and vascular thrombosis, using a large global federated database and (b) determine whether these results from a real‐world population were consistent with those of RCTs such as EMPA‐REG OUTCOME and DECLARE‐TIMI 58, which were conducted in selective study populations under stringent conditions. Here, SLC5A2 is linked to heart failure.